SpecificgyrAgene mutations predict poor treatment outcome in MDR-TB

Journal of Antimicrobial Chemotherapy - Tập 71 Số 2 - Trang 314-323 - 2016
Leen Rigouts1,2, Nele Coeck1,2, Mourad Gumusboga2, Willem Bram de Rijk2, K. J. M. Aung3, M A Hossain3, Krista Fissette2, Bruno Ledergerber4, Conor J. Meehan2, Bouke C. de Jong5,2,6, Armand Van Deun7,2
1Biomedical Sciences, University of Antwerp, Antwerp, Belgium
2Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
3Damien Foundation, Dhaka, Bangladesh
4Epidemiology Department, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
5Department of Medicine, Division of Infectious Diseases, New York University, New York, NY, USA
6Vaccinology Department, Medical Research Council Unit, Fajara, The Gambia
7International Union Against Tuberculosis and Lung Disease, Paris, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1186/1471-2334-11-78

10.1016/S0924-8579(03)00048-7

10.1179/joc.2005.17.2.169

Kocagöz, 1996, Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra, Antimicrob Agents Chemother, 40, 1768, 10.1128/AAC.40.8.1768

10.1093/jac/dki353

Singh, 2009, In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India, Indian J Med Res, 129, 542

10.1128/AAC.00287-09

10.1183/09031936.00134712

10.1128/JCM.00231-11

10.1089/mdr.2006.12.7

10.1099/jmm.0.046821-0

10.1378/chest.124.4.1476

10.1128/AAC.00968-10

10.5588/ijtld.14.0100

10.1093/jac/dkm061

Guillemin, 1998, Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria, Antimicrob Agents Chemother, 42, 2084, 10.1128/AAC.42.8.2084

10.1128/AAC.01380-07

10.1128/AAC.00036-08

10.1128/AAC.00541-09

10.1128/AAC.00920-10

10.1371/journal.pone.0120470

10.1371/journal.pone.0039754

10.1128/JCM.05286-11

10.1128/AAC.00042-11

10.1128/AAC.06272-11

10.1128/AAC.00707-11

10.3904/kjim.2011.26.2.153

10.1164/rccm.201212-2328OC

10.1164/rccm.201001-0077OC

WHO. Guidelines For The Programmatic Management Of Drug-Resistant Tuberculosis. Emergency Update 2008. WHO/HTM/TB/2008.402. 2008; 1–247. http://apps.who.int/iris/bitstream/10665/43965/1/9789241547581_eng.pdf .

WHO. Guidelines For Drug Susceptibility Testing For Second-Line Anti-Tuberculosis Drugs For DOTS-Plus . WHO/CDS/TB/2001.288. 2001; 1–13. http://apps.who.int/iris/bitstream/10665/83807/1/WHO_CDS_TB_2001.288_eng.pdf .

10.1128/JCM.00652-10

10.1016/j.tube.2011.03.001

10.1128/AAC.00204-15

10.1128/JCM.01001-15

10.1038/emi.2014.21

Mitchison, 1998, Standardisation of sensitivity tests, Int J Tuberc Lung Dis, 2, 69

WHO. Guidelines For Surveillance Of Drug Resistance In Tuberculosis . Fourth Edition. WHO/HTM/TB/2009.422. 2009; 1–83. http://apps.who.int/iris/bitstream/10665/44206/1/9789241598675_eng.pdf .

10.1371/journal.pone.0012245

10.1128/AAC.00177-09

10.1111/j.1469-0691.2011.03551.x

Rodríguez, 2003, In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis, Int J Antimicrob Agents, 20, 464, 10.1016/S0924-8579(02)00239-X

10.1128/AAC.01036-07

10.1056/NEJMoa055191

10.1371/journal.pone.0067030

10.1056/NEJMoa1315817

Esterly, 2010, Comparison of clinically significant cardiovascular events between three fluoroquinolones. Authors' response, Pharmacotherapy, 30, 479e

Thông tin
Thông tin xuất bản

Journal of Antimicrobial Chemotherapy

Tập 71 Số 2

314-323

Thông tin tác giả